Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00284089 |
The purpose of this study is to investigate the safety, efficacy, and pharmacokinetics of ranibizumab in the treatment of subfoveal CNV secondary to AMD
Condition | Intervention | Phase |
---|---|---|
Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-Related Macular Degeneration (AMD) |
Drug: Ranibizumab |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Open-Label Multicenter, Phase I/II Study Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Study ID Numbers: | CRFB002A1201 |
Study First Received: | January 30, 2006 |
Last Updated: | November 17, 2006 |
ClinicalTrials.gov Identifier: | NCT00284089 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Subfoveal CNV, AMD, ranibizumab |
Metaplasia Eye Diseases Choroid Diseases Neoplasm Metastasis Retinal Degeneration |
Macular Degeneration Neovascularization, Pathologic Retinal Diseases Retinal degeneration Choroidal Neovascularization |
Uveal Diseases Neoplasms Neoplastic Processes Pathologic Processes |